Twist Bioscience Corporation $TWST Shares Purchased by Baillie Gifford & Co.

Baillie Gifford & Co. increased its holdings in Twist Bioscience Corporation (NASDAQ:TWST) by 62.8% in the 3rd quarter, according to its most recent disclosure with the SEC. The firm owned 1,262,739 shares of the company’s stock after acquiring an additional 487,052 shares during the period. Baillie Gifford & Co. owned approximately 2.09% of Twist Bioscience worth $35,533,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the business. Universal Beteiligungs und Servicegesellschaft mbH grew its holdings in shares of Twist Bioscience by 822.2% during the 3rd quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 65,590 shares of the company’s stock worth $1,846,000 after purchasing an additional 58,478 shares during the period. Campbell & CO Investment Adviser LLC lifted its position in Twist Bioscience by 227.6% in the third quarter. Campbell & CO Investment Adviser LLC now owns 47,200 shares of the company’s stock valued at $1,328,000 after buying an additional 32,792 shares during the last quarter. Conestoga Capital Advisors LLC boosted its stake in Twist Bioscience by 95.8% during the third quarter. Conestoga Capital Advisors LLC now owns 55,600 shares of the company’s stock worth $1,565,000 after buying an additional 27,210 shares during the period. Peregrine Capital Management LLC increased its position in shares of Twist Bioscience by 34.9% during the third quarter. Peregrine Capital Management LLC now owns 292,153 shares of the company’s stock valued at $8,221,000 after acquiring an additional 75,571 shares during the last quarter. Finally, Benjamin Edwards Inc. raised its stake in shares of Twist Bioscience by 18.4% in the 3rd quarter. Benjamin Edwards Inc. now owns 28,323 shares of the company’s stock valued at $797,000 after acquiring an additional 4,410 shares during the period.

Wall Street Analyst Weigh In

TWST has been the subject of a number of research analyst reports. TD Cowen reaffirmed a “buy” rating on shares of Twist Bioscience in a research report on Thursday, January 8th. Barclays raised their price target on Twist Bioscience from $37.00 to $39.00 and gave the stock an “overweight” rating in a research report on Monday, December 15th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Twist Bioscience in a research note on Monday, December 29th. Stephens assumed coverage on Twist Bioscience in a research note on Monday, November 3rd. They set an “overweight” rating and a $41.00 target price on the stock. Finally, Evercore ISI reaffirmed an “outperform” rating and issued a $42.00 target price on shares of Twist Bioscience in a research report on Monday, January 5th. Eight analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $44.67.

Insider Activity

In other Twist Bioscience news, SVP Paula Green sold 6,920 shares of the stock in a transaction that occurred on Thursday, October 30th. The shares were sold at an average price of $31.44, for a total value of $217,564.80. Following the sale, the senior vice president directly owned 143,271 shares of the company’s stock, valued at approximately $4,504,440.24. This represents a 4.61% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, CFO Adam Laponis sold 5,517 shares of Twist Bioscience stock in a transaction on Thursday, October 30th. The stock was sold at an average price of $31.44, for a total transaction of $173,454.48. Following the sale, the chief financial officer directly owned 111,008 shares of the company’s stock, valued at approximately $3,490,091.52. This trade represents a 4.73% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 66,437 shares of company stock worth $2,136,365. Insiders own 3.08% of the company’s stock.

Twist Bioscience Price Performance

Shares of NASDAQ TWST opened at $42.94 on Friday. The company has a debt-to-equity ratio of 0.03, a current ratio of 3.64 and a quick ratio of 3.33. The company has a market cap of $2.63 billion, a price-to-earnings ratio of -32.78 and a beta of 2.19. The stock’s 50-day moving average is $33.70 and its two-hundred day moving average is $31.46. Twist Bioscience Corporation has a 1-year low of $23.30 and a 1-year high of $55.33.

Twist Bioscience (NASDAQ:TWST) last announced its quarterly earnings data on Friday, November 14th. The company reported ($0.45) EPS for the quarter, missing analysts’ consensus estimates of ($0.40) by ($0.05). Twist Bioscience had a negative return on equity of 27.40% and a negative net margin of 20.63%.The company had revenue of $99.01 million for the quarter, compared to analyst estimates of $97.40 million. Analysts forecast that Twist Bioscience Corporation will post -2.12 EPS for the current fiscal year.

About Twist Bioscience

Twist Bioscience Corporation is a synthetic biology company specializing in the development and commercialization of DNA-based products and solutions. Founded in 2013 and headquartered in South San Francisco, California, the company has pioneered a proprietary silicon-based DNA synthesis platform designed for high-throughput production of synthetic genes and oligonucleotides. Twist leverages semiconductor manufacturing techniques to enable precise, scalable synthesis of DNA at speeds and volumes unattainable with traditional methods.

At the core of Twist’s offering is its proprietary platform that automates the synthesis of custom DNA fragments, gene libraries, and long oligonucleotides.